Insmed's Arikayce Meets Goal in Label Expansion Study, Shares Rise 6%

Insmed's INSM stock rose 6% after positive top-line results from the phase IIIb ENCORE study for Arikayce in mycobacterium avium complex lung disease. The combination therapy met its primary endpoint and several key secondary endpoints, supporting regulatory submissions for label expansion in newly diagnosed patients. This could expand Arikayce's addressable market from 30,000 to over 200,000 patients, supporting blockbuster-level sales.